Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
6(100.0%)
6Total
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04097652Phase 1Unknown

Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke

Role: lead

NCT04893174Phase 1Unknown

Mesenchymal Stem Cells for The Treatment of Knee Osteoarthritis (KOA).

Role: lead

NCT04914403Phase 1Unknown

Mesenchymal Stem Cells for The Treatment of Frailty Syndrome

Role: lead

NCT03631420Phase 1Recruiting

Mesenchymal Stem Cells for Prevention of Bronchopulmonary Dysplasia in Infants

Role: lead

NCT04206007Phase 1Unknown

Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary Disease

Role: lead

NCT04347967Phase 1Unknown

Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS)

Role: lead

All 6 trials loaded